A new research study by Transparency Market Research (TMR) presents an exhaustive assessment of the global market for myelofibrosis. The research report, titled “Myelofibrosis Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 – 2024,” assesses the prominent trends, growth drivers, hindrances, market potentials, opportunities, and the challenges to find out the future prospects and performance of this market.
Get Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=17144
As per the research study, the increasing prevalence of cancer across the world is the key factor behind the substantial rise of the global market for myelofibrosis. The rising base of geriatric population is another important factor that is boosting this market substantially, states the research report.
The global market for myelofibrosis can majorly be assessed on the basis of treatment type, drug class, end user, and the geography. Based on the treatment type, the market can be classified into blood transfusion, androgen therapy, chemotherapy, and stem cell/bone marrow transplantation. Based on the drug class, the market can be categorized into immunomodulators, hydroxyurea, and JAK inhibitor (Ruxolitinib). Based on the end user, the market can be divided into hospitals, bone marrow transplant centers, and clinics.
By the geography, the market can be segmented into North America, Asia Pacific, Europe, the Middle East and Africa, and Latin America. North America, among these, is anticipated to dominate the global market over the next few years on account of the high prevalence of cancer, states the research report.
A comprehensive analysis of the competitive landscape prevalent in this market is also offered in this research report. Novartis, Merck & Co., Roche, Eli Lilly, Amgen, Celgene, Bristol-Myers Squibb, Gilead Sciences, and Incyte Corp. are some of the leading players in the global market for myelofibrosis, reports the market study.